20 May 2021>: Articles
Protein-Activated Kinase 3 (PAK3)-Related Intellectual Disability Associated with Combined Immunodeficiency: A Case Report
Rare coexistence of disease or pathology
Ohood Almutairi A* , Hessah A. Almutairi A , Maysoun Al Rushood ADOI: 10.12659/AJCR.930966
Am J Case Rep 2021; 22:e930966
Table 2. Selected laboratory test results of the patient.
Immune variant | Results | Reference range | ||
---|---|---|---|---|
2016 | 2018* | 2019 | ||
IgG, g/L | 3.91 | 4.39 | 6.17 | 4.9–16.1 |
IgG1, mg/L | 2590 | N A | NA | 3060–9450 |
IgG2, mg/L | 574 | NA | NA | 605–3450 |
IgG3, mg/L | 381 | NA | NA | 99–1221 |
IgG4, mg/L | NA | NA | 18–1125 | |
IgA, g/L | 0.0859 | 0.4–2 | ||
IgM, g/L | 0.266 | 0.615 | 0.302 | 0.5–2 |
Avg total CD3 T cells/μL (%) | 746 (83.48) | 766 (86.71) | 478 (86.67) | 1400–3700 (60–76) |
CD3 CD4+ helper T cells/μL (%) | 172 (17.87) | 179 (20.31) | 148 (27.16) | 700–2200 (31–47) |
CD3 CD8+ T cells/μL (%) | 561 (58.41) | 479 (54.42) | 257 (47.19) | 490–1300 (18–35) |
CD19 B cells/μL (%) | 84 (10.15) | 83 (9.34) | 41 (7.36) | 390–1400 (13–27) |
CD16 CD56+ NK cells/μL (%) | 50 (6.07) | 47 (5.30) | 28 (5.19) | 130–720 (4–17) |
Anti-diphtheria IgG, IU/mL | 0.132 | 0.03 (Jan 2018); 0.06 (Feb 2018) | NA | 0.01–0.1 |
Anti-tetanus toxoid IgG, IU/mL | 0.143 | 0.11 (Jan 2018); 0.140 (Feb 2018) | NA | 0.01–0.1 |
Anti-HIB IgG, mg/L | 0.123 | NA (Jan 2018); 0.027 (Feb 2018) | NA | 0.15–1 |
Anti-PCP IgG, g/L | 6.72 | NA (Jan 2018); 0.936 (Feb 2018) | NA | 10–30 |
HIB – type b; Ig – immunoglobulin; NK – natural killer; NA – not applicable; PCP – pneumocystis pneumonia. * A diphtheria/tetanus vaccine booster was given in January 2018. |